Stay updated on MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial
Sign up to get notified when there's something new on the MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial page.

Latest updates to the MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedLocations sections for Alberta, New Brunswick, and Ontario have been added under the Study Locations, and the prior provincial location subsections have been removed. The page revision tag has been updated to v3.3.3.SummaryDifference0.4%

- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check42 days agoChange DetectedThe Publications section now includes a note that items are automatically filled from PubMed. The revision tag updates from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check49 days agoChange DetectedThe government funding lapse notice has been removed from the page, and this does not affect the study details or core content; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check71 days agoChange DetectedSubstantive study details (eligibility criteria, interventions, primary/secondary outcomes, and locations) appear unchanged. Minor formatting differences observed do not affect the content.SummaryDifference0.4%

- Check92 days agoChange DetectedNew operating-status notice and version update to v3.2.0; previous v3.1.0 version tag removed.SummaryDifference2%

- Check100 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0; no other content changes provided.SummaryDifference0.0%

Stay in the know with updates to MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial page.